Aspira Women's Health
Aspira Receives Delisting Notice, Announces Plans to Appeal the Decision
The firm received notice that it had failed to regain compliance with the Nasdaq's requirement to maintain a minimum $35 million market value of listed securities.
In Brief This Week: Abbott, Personalis, Aspira Women's Health, Thermo Fisher Scientific, Illumina, More
News items for the week of Nov. 4, 2024.
ARPA-H Awards $110M to Commercial, Academic Teams Tackling Women's Health
The awardees included several diagnostics firms, among them Aspira Women's Health, which received $10 million for development of its EndoMDx test.
Aspira Receives NY State Approval for OvaWatch Test
Aspira can now offer the test, intended for assessing ovarian cancer risk in women with an adnexal mass, to patients in New York state.
In Brief This Week: Quest Diagnostics; Aspira Women's Health; Trinity Biotech; VolitionRx; DNANudge
News items for the week of Aug. 12, 2024.
Aug 23, 2022
Aspira Women's Health Prices $9M Public Offering
Mar 23, 2022